Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone-controlled study.

CONCLUSIONS: The study did not demonstrate assay sensitivity. The finding that both primary endpoints for tapentadol PR were not met can thus not be interpreted. Tapentadol PR was better tolerated than oxycodone CR, largely due to fewer gastrointestinal side effects. PMID: 28537501 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research